摘要
肝硬化门脉高压形成的机制主要是肝内阻力增加和门脉血流量增多.肝内阻力增加是始动因素,其原因主要分机械性和动力性因素;机械性因素是不可逆的,而动力性因素是可逆的.近年来发现许多血管活性物质可以解除或是减弱这种可逆性的梗阻.而且目前的外科分流术和经颈静脉肝内门体分流术可能引起许多并发症如肝性脑病、支架再梗阻等.于是,人们对门脉高压的药物治疗进行了大量的实验研究并有了许多新的认识.本文将主要阐述门脉高压的药物治疗的新进展.
Intrahepatic vascular resistance augmentation and portal blood flow increase are main mechanisms of portal hypertension.The former as an initial factor is mainly due to liver structure changes and motivity changes（reversible）.It has been demonstrated that this reversible resistance can be reduced by 20%-30% with drugs.Portosystemic shunt or transjugular intrahepatic portosystemic shunt（TIPS）may induce many severe complications such as hepatic encephalopathy and stent re-obstruction.Therefore,researchers have performed plenty of experimental investigations about drug treatment of portal hypertension,and this article introduces their new advances in this field.
出处
《世界华人消化杂志》
CAS
北大核心
2008年第33期3775-3781,共7页
World Chinese Journal of Digestology
关键词
门静脉高压
药物
治疗
Portal hypertension
Drug
Treatment
